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The Annual Northern Cape Colonoscopy Outreach program provides surveillance 
colonoscopy to high–risk individuals known with Lynch syndrome along the west 
coast and in the Northern Cape Province of South Africa. There are currently over 100 
known mutation positive individuals. Surveillance colonoscopies are performed 
annually in August/September, and are preceded a by a preparation visit 
approximately 6-8 weeks prior. The aim of the preparation trip has been to directly 
impart information, regarding preparation and importance of attendance, to individuals 
required to attend annual surveillance. During the preparation trip an attempt is made 
to reach all individuals scheduled for surveillance but due to the vastness of the 
Northern Cape inevitably every year some areas are not visited. It has been noted that 
over the past few years fewer than 25 % of the total participants obtained 100 % 
adherence to surveillance.1 
 
Objectives  
The primary objective of this study is to determine whether there is a need for a yearly 
colonoscopy preparation visit to high–risk individuals in the Northern Cape. The study 
determines if direct interaction with patients prior to surveillance colonoscopy will 
significantly impact attendance and adequacy of bowel preparation. 
 
Methods 
Seventy-eight individuals known with a genetic mutation for Lynch syndrome were 
enrolled in this randomised crossover trial spanning two years of surveillance. In 2014 
the control group of individuals had bowel preparation and instructions forwarded to 
their local clinics and distributed to them via clinic or hospital staff. The intervention 
group of individuals were personally visited and provided with instructions and bowel 
preparation by the research team. In 2015 there was a crossover of the control and test 
groups. A measurement of attendance at surveillance colonoscopy as well as 
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cleanliness of the colon was recorded for each year of study.  
 
Results  
The study cohort consisted of 28 (36%) male and 50 (64%) female participants with a 
median age of 39.5 years. Groups A and B consisted of 38 and 40 participants 
respectively. In September 2014 thirty-six (46.2%) participants presented for annual 
surveillance colonoscopy, 19 (50%) from the control group and 17 (42.5%) from the 
intervention group. In 2015 there were 41 (53%) compliant individuals; this included 
21 (55%) individuals receiving a preparatory direct contact visit, and 20 (50%) 
individuals from the 2015 control group. Following exclusion of carry-over and period 
effect, the study intervention was found not to significantly impact attendance (P = 
0.853). Superior attendance was noted in individuals with prior compliance to 
surveillance (P = 0.001). 
 
Conclusions 
Direct interaction with known Lynch syndrome individuals prior to annual 
surveillance colonoscopy has not shown to positively impact attendance. Interaction 
and counselling should focus on individuals identified to be defaulting surveillance. 
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Chapter 1 – Literature review 
 
1.1 Introduction 
Lynch Syndrome and the association with colorectal, and other cancers, is briefly 
described. The genetics, incidence and global impact of LS are reviewed. Current data 
with regards to screening, surveillance and adherence to colonoscopy are appraised 
and the influence of interactive communication is evaluated. 
 
1.2 Search methods 
A literature search of relevant literature was performed initially in April 2014 and 
repeated for new references in April 2015 and February 2017. The literature search 
was conducted using PubMed (MEDLINE), PubMed Central and the Medical Subject 
Headings (MeSH) databases. The following search term categories were used in 
combination: “Lynch syndrome”, ”HNPCC”, “South Africa”, “surveillance 
colonoscopy”, “screening colonoscopy”, “adherence”, “uptake”, “compliance” and 
“communication”. The search terms were used for title, abstract, keywords and full 
text fields. All result types were included. Further sources were identified by following 
up internal citations and references within the documents retrieved in the initial search. 
Some South African sourced articles were obtained directly from the author. This 
review excludes studies that have not been published in English and research currently 
underway. 
 
1.3 Colon cancer 
1.3.1 Classification 
The	   manner	   in	   which	   colorectal	   cancer	   originates	   and	   is	   expressed	   can	  
distinguish	   three	   forms: sporadic, familial and hereditary. The sporadic form of 
tumours appears in individuals carrying no mutation making them susceptible to 
developing colorectal cancer. This is by far the most common form of CRC (between 
60 and 80%).2 CRC is most common over the age of 50 and has been etiologically 
associated with dietary and environmental factors. 
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Familial colorectal cancer type X (fCRCtX), which has no associated identifiable 
gene, constitutes 20–40% of cases. Population studies show that there is a greater risk, 
two to three times higher than in the normal population, of developing this tumour 
when family members of primary consanguinity have suffered from sporadic colon 
cancer.3 
Hereditary CRC has two tumour variants that can be distinguished by the 
predisposition to the development and presence of adenomatous polyps or not. The 
diseases with polypoid features include familial adenomatous polyposis (FAP), 
MUTYH-associated polyposis (MAP), and the hamartomatous polyposis syndromes 
(Peutz-Jeghers, juvenile polyposis, phosphatase and tensin homolog (PTEN) 
hamartoma tumour syndrome – Cowden syndrome). HNPCC, or Lynch syndrome 




Colon cancer is the result of an accumulation of genetic alterations that drive the 
transformation of a normal cell to a malignant cell. The development of CRC is 
influenced by both genetic and environmental factors. The genetic factors influencing 
the progression to CRC can be sporadic or, as in Lynch syndrome, inherited. A fairly 
limited number of oncogenes and tumour-suppressor genes are mutated in a 
considerable fraction of CRCs, most significantly the adenomatous polyposis coli 
(APC), KRAS, and p53 genes. A greater group of genes that are mutated in subsets of 
CRC have begun to be defined. In association with DNA-methylation and chromatin-
structure changes, the mutations act to dysregulate conserved signalling networks that 
exert context-dependent effects on critical cell phenotypes. These mutations ultimately 
impact on the regulation of cellular metabolism, proliferation, differentiation, and 
survival.4 
Molecular studies of CRC have revealed that several signalling pathways are involved 
in its development. These pathways lead to the morphological heterogeneity of CRC, 
in terms of site, grade and type of the tumour. Three main pathway concepts have now 
been developed. The first clarified is the classical pathway, of which chromosomal 
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instability (CIN) is a hallmark. CIN is involved in roughly 80% of colorectal 
carcinomas. Most of these are due to loss of function mutations of the APC gene 
(responsible for familial adenomatous polyposis (FAP)). APC mutations also occur in 
sporadic CRC these however are not germline but somatic.5 Additional molecular 
events are activating mutations of KRAS and BRAF proto-oncogenes. The 
progression of an adenomatous polyp into a malignant carcinoma is now known as the 
adenoma-carcinoma sequence (Fig. 1).6 Vogelstein supplemented this concept with 
molecular data.7 
The microsatellite instability (MSI) pathway is responsible for the development of 
hypermutating carcinomas in which the adenoma-carcinoma sequence occurs 
precipitously. The prototype of these pathways was discovered in the early 1990s 
while searching for the molecular genetic origins of HNPCC.8 
 
Fig. 1: Adenoma–carcinoma sequence model in colorectal cancer6 
 
 
In 1994 it was discovered that Lynch syndrome is caused by a mutation in one of the 
genes encoding the proteins involved in DNA mismatch repair.9 MMR corrects routine 
errors such as single base mismatches or deletions and short insertions occurring 
during DNA replication. The proteins involved in MMR form a protein complex, this 
complex binds the mismatch and uses the information from the (correct) 
complementary strand to excise the error and repair it. When MMR does not function, 
the cells accumulate errors, which occur also in microsatellite sequences. Mismatch 
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repair proteins (MLH1, MSH2, MSH6 and PMS2) are easily detectable by 
immunohistochemistry in routinely processed tissue sections and are used as screening 
for Lynch syndrome.10 Lynch syndrome is responsible for about 3% of CRC, but MSI 
occurs in around 12% of sporadic tumours in the colon.5  
The CpG island hypermethylation phenotype (CIMP) pathway is a mechanism 
responsible for silencing of tumour suppressor genes and is involved in the regulation 
of transcription. The molecular events in the pathway include CIMP mutation of the 
BRAF gene. Carcinomas with CIMP were noted to be associated with serrated 
precursor lesions. Current evidence suggests that the risk of carcinoma evolution via 
CIMP is lower than the risk of progression of traditional adenomas.11 
 
1.3.3 Incidence  
Colorectal cancer is the third most common cancer in men (10% of cancers) and the 
second in women (9.2% of cancers) worldwide (Fig. 2). Africa demonstrates the 
lowest rates of CRC, approximately 16 000 new cases annually in men and 15 000 in 
women. 
 
Fig. 2: Estimated global age-standardised incidence rates per 100,00012 
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The most recent formal statistics available for CRC in South Africa, according to the 
National Cancer Registry, were histologically diagnosed during 2010 (table 1).13 In the 
Northern Cape the annual incidence of CRC was 3.7/100 000 population (3.5/100 000 
for men and 3.9/100 000 for women).14 
 
Table 1: Incidence and risk of colorectal cancer in South Africa13 
2010 No of cases Lifetime risk Percentage of all 
cancers 
 Male Female Male Female Male Female 
Total 1295 1132 1:114 1:182 4.77% 3.80% 
Asian 100 71 1:51 1:97 13.62% 7.39% 
Black 407 397 1:264 1:389 3.84% 2.54% 
Coloured 180 144 1:79 1:103 5.64% 4.66% 
White 608 520 1:50 1:71 4.83% 5.17% 
 
1.4 Lynch syndrome 
Lynch syndrome is a hereditary syndrome of the HNPCC variant. It carries a genetic 
predisposition to CRC, as well as extracolonic malignancies, and is the most common 
cause of hereditary colon cancers. The syndrome was first described in 1913 by Alfred 
Warthin and further characterised by Henry Lynch in 1974.15 In 1984 Boland and 
Troncale coined the term Lynch syndrome to refer to this disorder.16 Hereditary non-
polyposis colorectal cancer is now termed Lynch syndrome when there is a known 
causative genetic mutation.  
 
1.4.1 Genetics 
 Lynch syndrome is inherited in an autosomal dominant manner, and equally affects 
male and female family members. By designation, LS is associated with DNA 
mismatch repair gene mutations. There are four MMR genes that are linked to LS, 
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MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6) and 
postmeiotic segregation 2 (PMS2). Among individuals with identifiable germline 
mutations in the MMR genes, mutations in MLH1, MSH2, MSH6, and PMS2 are 
found in approximately 32, 39, 15, and 14 %, respectively.17 In addition, deletions of 
the terminal codon of the epithelial cell adhesion molecule (EPCAM) gene, located 
alongside the MSH2 gene, result in silencing of the MSH2 gene in tissues that express 
EPCAM. This deletion produces a phenotype very similar to LS.  
As previously described, the inactivation of these MMR genes causes an alteration in 
the repetitive sequences or microsatellites (the MSI pathway) leading to a prompter 
progression of the adenoma-carcinoma sequence. The adenoma-carcinoma sequence in 
LS is estimated at 35 months compared with 10-15 years in sporadic cancer.18 
CRC develops earlier in patients with a known germline mutation in one allele of a 
MMR gene, and the second allele (inherited from unaffected parent) is somatically 
inactivated by either somatic mutation, loss of heterozygosity, or epigenetic silencing 
by promoter hypermethylation. Thus, the tumours occur after somatic biallelic gene 
inactivation, with one mutation inherited and the other acquired. 
 
1.4.2 Incidence 
The incidence Lynch syndrome is approximately 2-3%.19,20 In the United States the 
population incidence of LS, based on the 2.8% incidence of LS among newly 
diagnosed CRC, is approximately 1 in 370.19  
Carriers of an MMR gene mutation have a very high risk of developing CRC. Most 
reports of lifetime risks of CRC for MLH1 and MSH2 gene mutation carriers range 
from 35 to 70%.20–23 The lifetime risk of CRC in LS appears to be dependent on 
gender and the MMR gene mutated. 
Patients with a known gremline MMR mutation are at increased risk for extracolonic 
neoplasms. The most common extracolonic tumour in Lynch syndrome is endometrial 
cancer. The risk of endometrial cancer varies depending on the MMR mutation. 
Following CRC, MMR mutation carriers showed a 12% (95% CI = 8-17%) 10-year 
risk for endometrial cancer.24 In another series the estimated ten-year cumulative risk 
of endometrial cancer subsequent to CRC was 23.4% (95% CI = 15–36%) for Lynch 
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syndrome women.25 The lifetime risk of cancers has been shown to vary according to 
the carriers Lynch genotype. (table 2)  
Lynch syndrome‐related tumours include colorectal, endometrial, stomach, ovarian, 
pancreas, ureter, renal pelvis, biliary tract and brain tumours, sebaceous gland 
adenomas and keratoacanthomas, and carcinoma of the small bowel. 
 
Table 2: Lifetime cancer risk relative to MMR genotype19–24,26,27 
Cancer site MLH1 MSH2 MSH6 PMS2 
Any Lynch 
cancer 
44-79% 38-78% 25-65% 16-53% 
Colorectal 50-65% 35-70% 18-69% 15-20% 
Endometrial 57-66% 21% 12-44% 15% 
Ovarian 20% 24% 1%  
Upper Urological 0.4-2.1% 9-20% 0.7%  
Gastric 6% 2% 4-6%  
Small bowel 3-6% 3-6%   
Biliary/ 
Pancreatic 
4%    
Brain (gliomas) 1.7% 2.5%   
 
In the Northern Cape Province of South Africa, an area with a low incidence of 
colorectal cancer (3.7/100 000)14, 10.5% of colorectal cancers were found to have 
MMR mutation on immunohistochemical testing.28 This was noted to be 
approximately three times the reported rate in high-incidence areas. 
 
1.5 Screening for Lynch syndrome 
1.5.1 Risk assessment 
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A detailed family history can assist in identifying families who should be referred for 
further testing to diagnose or exclude Lynch syndrome. In 1989, the Amsterdam 
criteria (table 3) were proposed in order to provide reliable family material required 
for international collaborative studies. Revision of these criteria in 1999 included 
various extracolonic tumours. The sensitivity and specificity of Amsterdam II criteria 
for a diagnosis of Lynch syndrome are 22 and 98 %, respectively.29 
 
Table 3: Amsterdam II criteria for gene testing for Lynch syndrome 
There should be at least three relatives with colorectal cancer (CRC) or with a 
Lynch syndrome‐associated cancer: cancer of the endometrium, small bowel, 
ureter or renal pelvis. 
• one relative should be a first‐degree relative of the other two 
• at least two successive generations should be affected 
• at least one tumour should be diagnosed before the age of 50 years 
• FAP should be excluded in the CRC case if any 
• tumours should be verified by histopathological examination 
 
In 1997, the Bethesda guidelines (table 4) were developed to identify individuals with 
CRC who should be tested for microsatellite instability.30 These guidelines were 
revised in 2004. The sensitivity and specificity of any one of the revised Bethesda 
criteria for a diagnosis of Lynch syndrome are 82 and 77 %, respectively.29 The 
revised Bethesda guidelines are shown to be an appropriate tool to help in selecting 
patients for genetic and MSI testing.31 
Several computational clinical prediction models exist, namely MMR predict, 
MMRpro and PREMM. These appear superior to existing clinical criteria, including 
the Amsterdam II and revised Bethesda guidelines, when determining an individual’s 
risk for LS. The overall sensitivity and specificity are above 90% for MMR predict 
and MMRpro.32 
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Table 4: Revised Bethesda guidelines for testing colorectal tumours for 
microsatellite instability 
1. CRC diagnosed in a patient aged <50 years. 
2. Presence of synchronous, metachronous colorectal or other Lynch 
syndrome‐related tumours, regardless of age. 
3. CRC with MSI‐H phenotype diagnosed in a patient aged <60 years. 
4. Patient with CRC and a first‐degree relative with a Lynch syndrome-
associated tumour*, with one of the cancers diagnosed at age <50 years. 
5. Patient with CRC with two or more first‐degree or second‐degree 
relatives with a Lynch syndrome‐associated tumour*, regardless of age. 
*LS-associated tumours include tumours of the colorectum, endometrium, stomach, ovary, pancreas, 
ureter, renal pelvis, biliary tract, brain, small bowel, sebaceous glands, and kerotoacanthomas. 
 
1.5.2 Clinical features 
Most patients with Lynch syndrome remain asymptomatic until they present with 
symptoms of colorectal cancer. Abdominal pain, gastrointestinal bleeding, a change in 
bowel habits, or loss of weight are often the presenting symptoms. Café au lait spots, 
cutaneous sebaceous gland tumours and keratoacanthomas are rarely found on 
physical examination. The colorectal cancers in Lynch syndrome differ from typical 
sporadic colorectal cancers in location, histology, and natural history.  
Individuals with Lynch syndrome tend to present at an earlier age and are at increased 
risk of synchronous and metachronous colorectal cancer. Metachronous colorectal 
cancers are new primary cancers diagnosed more than 12 months after the first 
diagnosis of primary colorectal cancer. In a cohort analysis of 332 subjects with LS 
who had segmental resections, 74 (22%) were diagnosed with metachronous CRC 
(incidence rate 23.6; 95%CI 18.8–29.7 per 1000 person-years). Cumulative risk of 
metachronous CRC was 16% at 10 years, 41% at 20 years and 62% at 30 years after 
segmental colectomy.32 Synchronous CRCs are more frequent in LS than in sporadic 
CRC. Approximately 7% of individuals with Lynch syndrome have more than one 
cancer by the time of diagnosis compared to 2.4% of the general population.33,34 
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Adenomas in Lynch syndrome tend to be flatter, are more often more proximal than 
sporadic adenomas. The development of cancer in LS is predominantly right sided 
(60-80%) when compared to 30% in sporadic MSI CRCs.35,36 
 
1.5.3 Pathological features  
Lynch-associated CRCs arise from adenomas but the progression of the adenoma-
carcinoma sequence in Lynch syndrome is thought to occur more promptly than in the 
CIS pathway CRCs, 35 months compared with 10-15 years.18 Adenomas are more 
likely to have high-grade dysplasia and/or villous histology as compared with sporadic 
adenomas.  
Histologically Lynch CRCs have the following features; poorly differentiated, tumour-
infiltrating lymphocytes, Crohn's like inflammatory reaction, mucinous, signet ring 
cells and medullary growth pattern. Despite these histological features, typically 
associated with a poorer prognosis, and the rapid progression of the adenoma–
carcinoma, Lynch-associated CRCs appear to have a better prognosis than the typical 
sporadic CRCs.  
Tumour genetics in Lynch-associated CRCs also differ fundamentally from CIN 
CRCs. Deficient mismatch repair is manifest as multiple changes of length mutations 
in nucleotide repeat sequences of tumour DNA when compared to normal mucosa of 
the same patient, termed high frequency microsatellite instability (MSI-H). MSI 
testing is performed using polymerase chain reaction (PCR) to amplify a standard 
panel of DNA sequences containing nucleotide repeats. MSI-H is found in over 90–
95% of colorectal cancers occurring as a consequence of Lynch syndrome.32,37 The 
sensitivity of MSI testing as a screening tool for LS is about 89% for mutations in 
MLH1 and MSH2. Mutations in MSH6 and PMS2A have a lower sensitivity, about 
77%. Specificity of MSI testing is approximately 90%. 38  
Immunohistochemical analysis of colorectal tumours is widely used for screening for 
LS. An initial 2-antibody panel has evolved into a 4-antibody panel (MLH1, MSH2, 
MSH6 and PMS2) detecting mutant MMR polypeptides. The use of 
immunohistochemistry (IHC) for analysis of tumours for MMR gene proteins has been 
shown to be a useful alternative to genetic analysis for the identification of MSI in 
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CRCs.10 In families with a high probability of having a mutation based on Amsterdam 
II or revised Bethesda criteria, IHC is the best first step because it may direct genetic 
mutation analysis.32 The sensitivity of IHC analysis is about 83% (regardless of the 
underlying MMR gene mutation), slightly lower than that of MSI analysis.38 
The high costs of testing all CRCs for MSI or loss of MMR protein (IHC) limits the 
use of pathological tumour testing as a screening method for LS.31 
 
1.6 Genetic testing for Lynch syndrome 
1.6.1 Tumour testing 
Tumour testing of CRCs by IHC and or testing for MSI can identify patients likely to 
have LS. The Evaluation of Genomic Application in Practice and Prevention (EGAPP) 
group from the United States Center for Disease Control and Prevention recommends 
testing all patients with CRC for LS by IHC or MSI testing. The Multi-Society Task 
Force endorses the testing of tumours in all patients with CRC 70 years of age or 
younger. In CRC patients older than 70 years thorough family history is essential for 
those in whom tumour testing is not done.31 
 
1.6.2 Germline testing 
In order to establish the diagnosis of Lynch syndrome germline testing for a 
deleterious mutation in the MMR gene is required.  Comprehensive germline testing 
involves gene sequencing and deletion/duplication DNA analyses so as to detect 
mutations in mismatch repair genes (MLH1, MSH2, MSH6, PMS2). Genetic 
identification of a pathogenic mutation in a LS pedigree assists in determining the 
status of at-risk family members.  
There are varied opinions with regards to germline genetic testing for MMR gene 
mutation. Traditional indications for LS genetic testing have been developed through 
authority consensus by several national organisations and associations  
In newly diagnosed CRCs, genetic testing for LS is indicated for affected individuals 
in families meeting Amsterdam I or II criteria or revised Bethesda guidelines, those 
with microsatellite unstable tumours by MSI/IHC testing, or individuals with >5% 
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chance of gene mutation by computer modelling.  
In known mutation positive families, identification of individuals with or without the 
mutation is possible by DNA testing. Any first-degree relative of individuals with a 
known MMR/EPCAM gene mutation should undergo site-specific genetic testing for 
the mutation known to the pedigree.31 
 
1.7 Colorectal cancer screening and surveillance in Lynch syndrome 
1.7.1 Screening and surveillance colonoscopy 
A screening colonoscopy is an examination performed on an asymptomatic person for 
the purpose of testing for the presence of colorectal cancer or colorectal polyps. 
Screening is based on risk of CRC determined by family history or genetic testing.  
Patients with a history of colonic polyps undergo surveillance colonoscopy at varying 
ages and intervals based on the patient's personal history of polyps, colorectal cancer, 
and/or gastrointestinal disease. Due to the high incidence of right-sided colonic polyps 
and cancers in LS adequate bowel preparation is essential in detecting these lesions. 
 
1.7.2 Guidelines for screening and surveillance 
The characteristic clinical and pathological features of these malignancies guide the 
prevention of CRC in LS families. A younger age of presentation, the predominance 
of right-sided colon cancers, and the rapid polyp growth with shorter time to malignant 
conversion indicate a need for further investigation. Studies have shown that the 
adenoma miss rate in LS carriers with conventional colonoscopy is more than 50%, 
and that many of these missed lesions are small, flat adenomas.40 Improved detection 
of small lesions by adequate bowel preparation is particularly important anticipating 
the accelerated carcinogenesis in LS. The use of intensive inspection (lasting >20 
min), narrow band imaging and autofluorescence endoscopy has been suggested to be 
more effective than standard colonoscopy in preventing CRC in LS.41  
Colorectal surveillance is the only surveillance protocol in Lynch syndrome proven to 
reduce CRC incidence, tumour stage and CRC-specific and overall mortality. There is 
however scant data offering guidelines for colonoscopic screening and surveillance in 
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patients with a known mutation. Current guidelines are largely based on expert 
opinion and limited observational data. Multiple studies have evidenced the efficiency 
of colorectal screening in decreasing CRC mortality (table 5).41–47 
Initial studies by Finnish group Järvinen et al showed a 62% reduction in CRC after 
10 years of surveillance when compared to the group that declined colonoscopy 
surveillance.42 In their 15-year follow-up, colonoscopic screening at 3-year intervals 
showed a reduced overall mortality by about 65% in mutation-positive families.48 
Although a 3-year interval between colonoscopies has been proved to be effective42 
more recent studies have noted a significant number of interval CRC developing 
within 1-2 years of a normal colonoscopy.41,46,47 Mecklin et al showed a 13.5% rate of 
interval CRC with screening colonoscopy every 2-3 years.45 Of the 21 CRCs detected 
by Stuckless et al, 8 were within 2 years of a normal colonoscopy.41 Further studies 
showed similar results, 13 of 34 and 16 of 33 interval CRCs were diagnosed within 2 
years of a previously normal screening colonoscopy.47,49  Engel’s prospective cohort 
study that included 1126 individuals from families with Lynch syndrome found the 
median time between the CRCs detected through follow-up colonoscopy and the 
preceding colonoscopy was less than 1 year (11.3 months).46 The proportion of 
interval cancers with a local tumour (Dukes A or B) varied from 78% to 95%. In all 
studies most interval cancers were diagnosed in individuals older than 40 years. 
Mecklin et al, however, showed that 20–30% of interval CRCs were diagnosed 
between the age of 30 and 40 years.45  
In 2014 the US Multi-Society Task Force on Colorectal Cancer published consensus 
guidelines for screening of high-risk individuals, these were in line with international 
consensus groups.31,39,50 Suggested screening for individuals with Lynch syndrome 
(known MMR/EPCAM mutation carriers) comprises colonoscopy every one to two 
years beginning at age 20 to 25 years, or two to five years prior to the earliest age of 
CRC diagnosis in the family (whichever is earlier). Families with MSH6 and PMS2 
mutations have been shown to have a lower-risk phenotype with a lesser risk of 
colorectal cancer and a later age at CRC diagnosis,21 thus colonoscopic screening is 
recommended to begin at age 25 to 30 or two to five years prior to the earliest CRC. 
The identification of cancers before age 30 in these mutation carriers has recently 
prompted the NCCN to retract its recommendation to start screening patients with 
	   26	  
MSH6 and PMS2 mutations at a later age.51 Screening recommendations, starting at 
age 25 – 30, remain the same regardless of the causative gene.  
 
Table 5: Intervals and outcomes of colorectal cancer surveillance in Lynch 
syndrome 







(Dukes A,B) % 
Järvinen et al 
199542 
133 3 0 deaths 100 
De Vos tot 
Nederveen 
Cappel et al 
200243 
857 <2 Not reported 93 
Dove-Edwin 
et al  200544 
554 3-5 72% reduced 
mortality 
Not reported 
Mecklin et al 
200745 
420 2-3 5 deaths* 80 
Engel et al 
201046 
1126 1 Not reported 95 
Vasen et al 
201047 
745 1-2 0 deaths 90 
Stuckless et 
al  201241 
152 1-2 11 deaths* 77 
*deaths associated with patient delayed diagnosis, due to poor compliance 
 
1.7.3 Adherence to surveillance colonoscopy 
Compliance with the recommended surveillance interval in a number of studies in 
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developed countries has been shown to be poor. In Europe and the United States 
compliance with surveillance varies between 58 and 93% in HNPCC family 
members.41,52–54 Solitary small studies have proposed that numerous individuals at risk 
for CRC do not have endoscopic surveillance as frequently as guidelines specify. 
Vasen et al and Stuckless et al showed noncompliance rates of 20% and 42% 
respectively.41,47 This is worrisome considering lack of participation in a colonic 
surveillance programme has shown to be associated with increased mortality due to 
CRC.42,45–47  
Attendance rates for endoscopic surveillance, used to define compliance, have varied 
from study to study thus making assessment of compliance complex. Research groups 
determining compliance rates have determined compliance based on participant 
attendance at one surveillance endoscopy only, presence within the last 2 years or have 
categorised compliance based on general surveillance intervals.47,53–55  
CRC screening studies in U.S. populations have recognised numerous factors related 
to improved screening commitment. Level of education, income, having health 
insurance, participating in other cancer screening tests, and receiving a 
recommendation from their physician for CRC screening improves uptake.56 A strong 
association has been observed between CRC screening uptake and the number of times 
a patient has seen a physician or been in contact with the health system.56 Compliance 
with appropriate surveillance for CRC in Lynch syndrome is shown to be higher 
among individuals with a personal history of CRC and those with a first degree 
relative with CRC at age <50.53 Genetic counselling and testing of patients prior to 
diagnosing LS has shown to significantly influence adherence to recommendations for 
colon cancer surveillance.53,57,58 
Multiple justifications have been realised to account for noncompliance to CRC 
screening. It is unclear whether unsatisfactory CRC surveillance is the result of patient 
non-compliance or improper physician recommendation for surveillance intervals. 
Stoffel et al noted that physician recommendations for less frequent colonoscopies 
appeared to be an important reason why subjects had colonoscopies less frequently 
than every 1–2 years and recommended physician communication as an important 
target for intervention.53 Delays due to incorrect interval planning and incorrectly 
discharging patients from surveillance have also impacted regular attendance of LS 
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patients.53 Hospital system errors have included delays in booking by endoscopy 
departments and the automatic discharge of patients if they failed to respond or 
attend.54  
Patient related non-attendance reasons have regularly included fear of discomfort or 
pain. A large Finnish study of 415 high risk patients undergoing surveillance found 
that painful experience of colonoscopy, especially in females, was seen as the primary 
risk for poor compliance.53,54,59 The financial liability of regular surveillance, 
nonresponse to contact from endoscopy departments, change of address without 
informing the hospital, and being pregnant or breastfeeding at the time of scheduled 
surveillance are also noted as grounds for poor attendance.53,54 Repeated delays in 
endoscopic surveillance seem to be related to particular patients who are 
noncompliant.  
 
1.7.4 Influence of communication on adherence to surveillance 
Effective communication occurs when a desired effect is the result of information 
sharing. It has been shown that effective clinician-patient communication is directly 
linked to improved patient satisfaction, adherence, and subsequently, health 
outcomes.60  
There are no studies reviewing the effects of direct communication on endoscopic 
surveillance in patients with Lynch syndrome. Data gathered relates to screening and 
surveillance of colorectal cancer in population-risk individuals. Patient contact 
methods have varied among research groups, with primary outcome measures 
predominantly being attendance or uptake of the indicated screening modality. 
Similarly, screening modalities also varied amongst research groups. Colonoscopy, 
flexible sigmoidoscopy and faecal occult blood tests (FOBT) are all noted as 
appropriate screening methods for CRC.  
A systematic review by Brouwers et al found that client reminders, small media 
(educational pamphlets, videos or websites), and provider audit and feedback appear 
to be reasonable strategies to increase the uptake of screening. Group and one-on-one 
educational intervention showed potential in increasing the uptake of CRC 
screening.61 A recent review from the Community Preventive Services Task Force 
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found robust evidence to support multicomponent interventions to improve CRC 
screening. Multi-component interventions include a combination of at least two 
interventions, to increase community demand, increase community access or to 
increase provider delivery of screening services.62 A large US randomised controlled 
trial of 21,860 patients demonstrated that personalised mailings to individual patients 
produced a modest increase in colorectal cancer screening. Once appropriately 
informed, most patients opt to be screened for colorectal cancer.63  
Colonoscopy adherence is often noted to be negatively affected by the painful 
experience of the investigation.53,54,59 Voiosu et al found that better interaction with 
patients prior to colonoscopy reduced the patient perceived burden of the 
investigation. Comfort during colonoscopy and the probability of better attendance is 
dependent on satisfaction with the information provided before the procedure.64 
Turner et al compared telephonic peer coach support with mailed professional 
brochures to promote attendance to colonoscopy screening. They found that for 
patients who often fail to keep appointments, peer coach support appears to benefit 
colonoscopy attendance more than an educational brochure.65 
The field of cross-cultural care focuses on the ability to communicate effectively and 
provide quality health care to patients from diverse sociocultural backgrounds. There 
is no empirical literature comparing the effectiveness of different models of cross-
cultural care and communication.66 In low-income minorities compliance with 
screening colonoscopy was improved by patient navigators to personally assist with 
overcoming organisational barriers.67 
Available data underscores the fact that informed patients can play an active role in 
achieving effective adherence to preventive services. 
 
1.8 Lynch syndrome in South Africa 
The first clinical description of LS in South Africa was in 1985. The diagnosis was 
based on an affected 30-year-old man who had developed colorectal cancer at the age 
of 19, and a detailed family pedigree showing autosomal dominant inheritance over 
three generations.68 
Data pertaining to Lynch syndrome within South Africa is sparse. The majority of this 
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data is related to a cohort of over 100 individuals with Lynch syndrome that have been 
identified by genetic testing of at-risk family members in the Northern Cape. 
 
1.8.1 Colorectal cancer screening and surveillance 
The Annual Northern Cape Colonoscopy Outreach program undertakes this platform 
intending to provide an annual mobile genetic testing and surveillance service in small 
district hospitals and clinics along the western coast of SA. At the age of 18 relatives 
of known LS individuals undergo genetic counselling and site-specific testing to 
ascertain a possible causative mutation. Patients identified as having an MMR gene 
mutation undergo yearly surveillance colonoscopy every 2 years starting at age 18, 
then annually from 30 years old. The mobile colonoscopy unit has shown to provide 
quality care for LS families in remote areas of South Africa.69  
In a study done by the University of Cape Town on previously identified families 
living in the Northern Cape Province, surveillance colonoscopy was coupled to 
improved overall, and CRC-related survival, in subjects carrying a single MMR gene 
mutation.55 In line with international findings, polyp pick-up is most predominant in 
the right-sided colon thus highlighting the significance of appropriate and 
comprehensive colon preparation prior to endoscopy.69 
   
1.8.2 Adherence to surveillance colonoscopy 
With each year of colonoscopy surveillance in the Northern Cape Province 
documentation of attendance is noted. Over the past years attendance at this outreach 
clinic has been less than desired.  In 2007 Bruwer et al documented poor uptake to 
colonoscopy surveillance. It was noted that fewer than a quarter of participants, 
attending for surveillance, had been adherent with all their recommended screening 
appointments.1 Major factors identified for noncompliance were financial constraints 
(18%) and transport related difficulties (16.4%). Unlike findings in international 
literature, the unpleasant experience of bowel preparation was found to have a 
significant negative impact adherence to surveillance (16.4%). In line with 
international findings, 16.8% of patients reported colonoscopy as uncomfortable and 
28.8% reported the investigation to be a painful experience. This however did not 
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Hereditary non-polyposis colorectal cancer (HNPCC), now known as Lynch syndrome 
when there is a known causative mutation, is the most prevalent of the inherited colon 
cancer susceptibility syndromes. Lynch syndrome is an autosomal dominant condition 
caused by a germline mutation in one of several DNA mismatch repair (MMR) genes. 
It is characterised by the development of colorectal, endometrial and various other 
cancers at a young age, with individuals at risk for synchronous and metachronous 
colorectal cancer (CRC) [2]. The lifetime risk of developing CRC is significantly 
higher in Lynch syndrome, and varied risk is seen with each genotype mutation. 
Lynch syndrome is shown to account for 2 to 3 per cent of all colon cancer cases in 
high incidence areas [3]. The adenoma-carcinoma sequence is thought to progress 
more precipitously in Lynch syndrome and new cancers have occurred within one to 
two years after what appeared to be a normal colonoscopy [4]. In Lynch syndrome, 
adenomas tend to be flatter, are more often proximal, and more commonly have high-
grade dysplasia and/or villous histology than sporadic adenomas. Like the adenomas, 
CRCs in Lynch syndrome are also more commonly proximal, thus highlighting the 
need for complete bowel preparation [5].  
In the Northern Cape Province, the annual incidence of colorectal cancer is 3.7/100 
000 population [6]. There is evidence that inherited colorectal cancer may account for 
a greater proportion of the disease burden in this population than would be expected 
[7].  
Endoscopic surveillance is the only surveillance protocol in Lynch syndrome proven 
to reduce CRC incidence, tumour stage and CRC-specific and overall mortality [5,8-
10]. Limited data is available offering guidelines for colonoscopic screening and 
surveillance in patients with a known Lynch mutation. Current guidelines are largely 
based on expert opinion and limited observational data. In 2014 the US Multi-Society 
Task Force on Colorectal Cancer published consensus guidelines for screening of 
high-risk individuals. These guidelines are in line with international consensus groups 
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[2,11,12]. Suggested screening for individuals with Lynch syndrome comprises 
colonoscopy every one to two years beginning at age 20 to 25 years, or two to five 
years prior to the earliest age of CRC diagnosis in the family (whichever is earlier) [2].  
There are no studies reviewing the effects of direct communication on endoscopic 
surveillance in patients with Lynch syndrome. Data gathered relates to screening and 
surveillance of CRC in population-risk individuals. Patient contact methods have 
varied among research groups, with primary outcome measures predominantly being 
attendance or uptake of the indicated screening modality [13,14]. Available data 
underscores the fact that informed patients can play an active role in achieving 
effective adherence to preventive services [15-17].  
Since 1988, the University of Cape Town and Groote Schuur Hospital has offered 
surveillance colonoscopy to high–risk individuals along the west coast and in the 
Northern Cape Province of South Africa. Initially surveillance was provided for 
suspected high–risk families based on family history. Mutational analysis was 
introduced in 1997 and this has led to the detection of 17 mutations in the MLH1 and 
MSH2 genes in 56 families [6,18]. One MLH1 mutation is common to 32 families and 
accounts for over 100 individuals identified with Lynch syndrome who require annual 
colonoscopic surveillance in the Northern Cape Province [18]. Annual colonoscopy in 
these subjects, carrying a single MMR gene mutation, has shown to be associated with 
improved overall and CRC-related survival [19]. The mobile service has shown to 
provide access to colonoscopy in remote areas without compromising the quality of 
service [20].  
Until now, biannual visits to the Northern Cape Province have been undertaken. 
Surveillance colonoscopy is done in August/September of every year and is preceded a 
by a preparation visit approximately 6-8 weeks prior to surveillance. The Annual 
Northern Cape Colonoscopy Outreach takes place over one week in four pre-
determined towns along the western coast of South Africa. The outreach colonoscopy 
service requires that all equipment and trained staff be provided as a mobile service. In 
order to aid attendance, prearranged transport has regularly been available to those 
individuals who do not have their own. Over the past few years it has been noted that 
fewer than 25 % of the total participants obtained 100 % adherence to colonoscopy 
screening. A significant number of individuals (16.4%) reported poor adherence to 
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bowel preparation as a reason for noncompliance with surveillance [1]. The preceding 
preparation visit was designed to directly impart information to participants 
undergoing regular surveillance as well as to deliver bowel preparation to rural areas 
(Fig. 3). In addition, new family members are identified for genetic counselling and 
testing of founder mutations. Effective clinician-patient communication is shown to be 
directly linked to improved patient satisfaction, adherence, and subsequently, health 
outcomes [20]. Each year an attempt is made to personally interact with and supply 
every at-risk individual with information pamphlets, in their preferred language, 
pertaining to colonoscopy preparation and the importance of adherence.  
The Northern Cape Province is the largest and most sparsely populated province of 
South Africa. Afrikaans first-language speakers predominate, about 68% of the 
population, with other primary languages being English, Setswana and Xhosa. During 
the preparation trip the team covers approximately two thousand kilometres in an 
attempt to reach all individuals scheduled for surveillance. It has been logistically 
impossible to cover the entire area in one week and inevitably every year some areas 
are not visited. This results in some patients receiving information with direct 
interaction from the team where as others receive the same information, as pamphlets 
alone, from medical staffs at local clinics. The current standard of care involves 
visiting as many towns as practical.  It is chance, finance and logistic difficulties that 
dictate whether subjects are visited during the preparation trip or not.   
The primary objective of this study was to determine whether there is a need for a 
yearly colonoscopy preparation visit to high–risk individuals in the Northern Cape 
Province. This study determines whether direct interaction with patients prior to 
surveillance colonoscopy will significantly impact attendance. The primary end point 
is measured by attendance at surveillance colonoscopy in September of the same year. 





A randomised controlled crossover trial was developed to take place over two years of 
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endoscopic surveillance by the Annual Northern Cape Colonoscopy Outreach 
Program. The trial period extended from July 2014 to September 2015, and involved 
four trips to the Northern Cape Province (2 preparation and 2 surveillance 
colonoscopy trips). 
Participants were selected from a cohort of 102 patients known and managed through 
the Colorectal Surgery Unit at Groote Schuur Hospital and the Division of Human 
Genetics at the University of Cape Town. Included participants were randomised to a 
control group that was not seen prior to colonoscopy, and a test group that was visited 
by a team from Cape Town in July of each study year. Randomising individuals was 
impractical as many were family members residing together. Randomisation was 
therefore achieved by dividing individuals into small groups of 5-10 based on area of 
residence (table 6).  
These smaller ‘town groups’ were then randomised to control and intervention groups. 
Randomisation was done by blindly withdrawing numbered town groups from a sealed 
container. Town groups 1, 2, 4, 5, 6 and 9 formed the control group (Group A) in 
2014. In the first year of study the control group of individuals had bowel preparation 
and instructions forwarded to local clinics. The clinics were asked to contact the 
participants and provide them with the required written information prior to their 
surveillance appointment. In July 2014, the intervention group (Group B) of 
individuals (town groups 3, 7, 8, 10, 11 and 12) were visited at their hometowns and 
personally provided with instructions and bowel preparation by the research team. In 
the second year of study the intervention on these groups was reversed.  
The majority of participants speak Afrikaans as a home language, thus all verbal and 
written communication was accomplished in each individuals preferred language. 
Consent was obtained from all individuals participating in this trial. This study adheres 
to the 2013 Helsinki Declaration and was approved by the University of Cape Town 
Human Research Ethics Committee (HREC REF: 352/2014). 
 
Inclusion and exclusion criteria 
All subjects undergoing surveillance colonoscopy, known to have a genetic mutation 
predisposing them to colon cancer, and had an intact colon, were included in this trial. 
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Individuals undergoing surveillance biannually were excluded. Participants 
undergoing colonic surgery within the study period were included in the primary 
outcome measure and excluded from secondary outcomes. 
 
Outcome measures 
Compliance and understanding of information given was measured in terms of 
attendance at the Annual Northern Cape Colonoscopy Outreach visit in September of 
each year of study. Adequacy of bowel preparation was assessed during colonoscopy 
by means of the Harefield Cleansing Scale [22]. (Fig. 4)  
Demographic, socio-economic, and clinical data were extracted from patient folders 
and recorded on an Excel data-capturing sheet. This included all patients who 
attended, as well as those who were expected to attend surveillance in each year of 
study.  
The personal experience of patients was reviewed by the completion of evaluation 
forms by those who attended colonoscopy screening in September 2014 and 2015.  
 
Statistical considerations 
A power study was done to determine sample size required for a study power of 90% 
(Fig. 5). This was based on the research team proposal that 70% of subjects would 
attend if personally visited during the preparation trip and 50% if they were not 
visited. With the consideration that this is a superiority trial, it was calculated that a 
total of 66 individuals (33 in each arm) were required to have a 90% chance of 
detecting, as significant at the 5% level, an increase in the primary outcome measure 
from 50% in the control group to 70% in the experimental group. A correlation 
assumption, using McNemar’s test, of 0.5 based on the proposal of attendance also 
correlates to a total of 66 patients required to detect significance.  
Statistical analysis was performed using Stata. Categorical variables of both arms are 
compared using correlates to a total of 66 patients required to detect. McNemar’s, 
Mainland-Gart and Prescott’s tests assess the treatment and period effects of 
crossover. 
	   43	  
Results  
 
We identified 56 families with a MMR germline mutation encompassing 102 
individual mutation carriers living in the Northern Cape Province and requiring annual 
surveillance. Twenty-three patients were excluded from the study as they had 
previously undergone colonic surgery, only requiring surveillance by flexible 
sigmoidoscopy. One patient died prior to the start date of the trial. Of the initial 102 
individuals identified to take part, seventy-eight (76.4%) were eligible for the trial. All 
participants contacted by the study coordinator, and subsequently by the researcher, 
agreed to participate. Figure 6 shows the patient flow through the clinical protocol. 
Two patients who presented for surveillance colonoscopy in 2015 did not undergo 
colonoscopy due to poor health. Three patients underwent colonic surgery within the 
two years of study. All three of these participants presented for surveillance in 2015 
and underwent flexible sigmoidoscopy. The study cohort consisted of 28 (36%) male 
and 50 (64%) female participants aged between 25 and 78 years (median 39.5 years). 
Groups A and B consisted of 38 and 40 participants respectively.  
The baseline demographic characteristics of the randomised patients are shown in 
table 7. There were no significant participant baseline differences between the two 
groups. Several participants living in rural Northern Cape towns were required to 
travel long distances to attend surveillance. The majority of participants (83.33%) 
necessitated a commute of up to 200 kilometres in order to attend annual surveillance. 
Forty-nine (62.82%) participants required arranged transport to travel from their 
hometown to the pre-determined location of outreach surveillance colonoscopy.  
On analysis of medical records, 85% of participants had attended at least one of their 
previously scheduled colonoscopy appointments. Of the 78 participants, only 51% 
attended surveillance colonoscopy in 2013, the year preceding this study. 
 
Primary outcome analysis 
In September 2014 36 (46.2%) participants presented for annual surveillance 
colonoscopy. Of the thirty-six individuals presenting 19 were from the control group 
(Group A) and 17 from the intervention group (Group B). Hence, 50% of individuals 
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receiving indirect contact, and 42.5% of individuals directly contacted prior to 
surveillance attended. In 2015, there were 41 (53%) compliant individuals; this 
included 21 (55%) individuals receiving a preparatory direct contact visit (Group A), 
and 20 (50%) individuals from the 2015 control group B.  
Twenty-seven (34.6%) of the 78 individuals presented for surveillance in both years of 
study, 14 from Group A and 13 from Group B. Twenty-eight (35.9%) participants did 
not attend both appointments. Group A, initially the control group, showed an increase 
in attendance to surveillance from 50% in 2014 up to 55% with intervention in 2015. 
Group B also showed an improved compliance in 2015, 42.5% to 50%, despite 
receiving intervention by direct contact in 2014 (Fig. 7). 
The period by treatment interaction was measured to exclude carry-over effect. 
Pearson’s chi square (one degree of freedom) and Fisher's exact test of association 
revealed p-values of 0.504 and 0.593 respectively (odds ratio (OR) 1.131). This result 
suggests no interaction. Calculation of the period effect of crossover suggests no 
period effect significance (P = 0.297). 
Assuming the absence of a carry-over effect and a period effect, the treatment effect 
was assessed by means of McNemar’s test. A p-value of 0.835 suggests there was no 
effect after intervention by the research team. This was confirmed by the Mainland-
Gart (P = 0.795) and Prescott tests of association (P = 0.855).   
 
Factors influencing primary outcomes  
Table 8 shows the effects of variables on the primary outcome. Age and gender 
showed no statistically significant impact on attendance to endoscopic surveillance. 
Although not statistically significant (P = 0.095), patients travelling shorter distances 
showed an inclination towards reduced attendance. Individuals having attended 
previously scheduled appointments were more likely to be compliant during the study 
period (P = 0.001; 95% confidence interval (CI)).  
Participants having attended more than 5 previous colonoscopies showed 54.2% 
attendance over two years. Those having undergone more than 10 prior surveillance 
scopes achieved 87.5% attendance (Fig. 8). 
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Secondary outcome analysis 
Seventy-seven participants were analysed for secondary outcomes, 36 in 2014 and 41 
in 2015. A total of 72 colonoscopies were done throughout the study period (Fig. 9). 
All of the 36 individuals attending surveillance in 2014 underwent colonoscopy. In 
2015, 36 of the 41 individuals attending underwent colonoscopy. As mentioned, five 
individuals were excluded from colonoscopy in 2015 despite having attended their 
appointment (2 from Group A, 3 from Group B).  
In 2014 and 2015 respectively, 34 of 36 (94.44%) and 35 of 36 (97.22%) individuals 
undergoing colonoscopy had been adequately prepared (Harefield A or B).  In 2014 
100% of individuals in the control group, not receiving direct contact, achieved 
adequate colonic preparation. There were only 3 failed colonoscopies due to poor 
preparation (Harefield C or D). Two of the failed colonoscopies belonged to the 
intervention group receiving direct contact prior to surveillance in 2014. 
 
Patient comment 
Fifty individuals supplied questionnaires for assessment. The majority of participants 
(96%) were satisfied with the information provided by brochures, regarding the 
communication adequate. Only 2 patients reported poor understanding of the provided 
written material. Despite considering the small media adequate, 22 individuals (44%) 
requested to be directly contacted by a doctor or nurse prior to surveillance 
colonoscopy. 
Upon assessment of self-reported motives for prior non-attendance the research group 
found that, of the 50 individuals, only 26 (52%) supplied reasons for not attending 
previously scheduled colonoscopy appointments. Ten individuals reported an 
unwillingness to undergo annual surveillance, presenting for appointments only when 
convenient. Five participants defaulted due to work commitments and 4 reported being 
ill on the date of scheduled surveillance. Two individuals were pregnant at the time of 
surveillance and one was incarcerated. Only three individuals reported an unpleasant 
prior experience as motive for non-compliance. Of these three, 2 reported bowel 
preparation to be intolerable. One patient did not attend because she was scared. 
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Discussion 
 
The results of this study demonstrate that 34.6% of the study population are compliant 
with the screening intervals suggested by consensus groups [2,11,12]. This is lower 
than European and United States compliance rates with surveillance varying between 
58% and 93% in Lynch syndrome family members [23-26]. Vasen et al and Stuckless 
et al reported noncompliance rates of 20% and 42% respectively [10,24].  
Direct contact with known Lynch syndrome individuals did not significantly improve 
adherence to surveillance (P = 0.835). Counselling and the provision of pertinent 
information by the research group 6 weeks prior to surveillance was not shown to 
improve attendance. In a systematic review by Brouwers et al client reminders and 
small media (educational pamphlets, videos or websites) appeared to be reasonable 
strategies to increase the uptake of screening. Group and one-on-one educational 
intervention showed potential in increasing the uptake of CRC screening [13]. In 
addition to annual counselling prior to surveillance all participating individuals have 
previously undergone genetic counselling and testing, thus were expected to have 
improved adherence to recommendations for CRC surveillance. Genetic testing in 
Lynch syndrome has shown to considerably improve compliance with CRC 
surveillance [25,27,28]. 
Available data underscores the fact that informed patients can play an active role in 
achieving effective adherence to preventive services, however the research 
intervention did not result in improved uptake. The probability of better attendance is 
likewise shown to be dependent on satisfaction with the information provided before 
the procedure [29]. The information provided at direct contact has been reviewed by 
the research team and found to be appropriate and given in each individual’s home 
language. Patient self-reports on the adequacy of information supplied showed that 
96% of participants understood the educational pamphlets provided. Despite 
reportedly understanding the pamphlets, almost half of the participants (44%) found it 
useful to directly interact with a health care provider prior to surveillance 
colonoscopy. This may indicate a need for better verbal communication with 
individuals undergoing CRC surveillance. 
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With advances in telecommunication infrastructure, particularly cellular messaging 
systems, in rural areas of South Africa, the research team has noted improved access to 
indirect communication within the study population. This may explain why 
intervention by direct contact showed no significant improvement in attendance.  
Inconsistent with previously published international literature regarding CRC 
screening, we have shown that surveillance adherence in known Lynch individuals in 
South Africa’s Northern Cape Province is not influenced by gender or age. 
Internationally, significantly more female mutation carriers less than 60 years of age 
have shown to take up and adhere to surveillance [24,30].  
Reduced health care coverage in rural areas has shown to adversely influence CRC 
screening uptake, however unpredictably, individuals travelling shorter distances 
showed an inclination towards reduced attendance. This may be due to pre-planned 
transport for individuals travelling from more remote areas. As noted in low-income 
minorities, compliance with screening colonoscopy was improved by personal 
assistance with overcoming organisational barriers [17].  
In-line with international findings a strong association has been observed between 
CRC surveillance uptake and the number of times a patient has seen a physician or 
been in contact with the health system [30]. In our cohort, patients known with prior 
satisfactory compliance were likely to retain their compliance. Compliance was noted 
to range from 15.1% in individuals with no or one prior surveillance colonoscopy, to 
87.5% in those having attended more than ten previous appointments. Prior 
compliance was the only variable shown to significantly influence attendance (P = 
0.001). Repeated delays in endoscopic surveillance seem to be related to particular 
patients who are non-compliant. This allows for identification and redirection of 
resources towards individuals requiring additional information and supportive 
counselling. 
Major factors previously identified for non-compliance in this study population were 
financial constraints (18%) and transport related difficulties (16.4%). In addition, 
16.8% of patients reported colonoscopy as uncomfortable and 28.8% reported the 
investigation to be a painful experience [1]. Patient related non-attendance reasons 
have regularly included fear of discomfort or pain [25,26,31]. A large Finnish study of 
415 high-risk patients undergoing surveillance found that the painful experience of 
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colonoscopy, especially in females, was seen as the primary risk for poor compliance 
[31]. Voiosu et al found that better interaction with patients prior to colonoscopy 
reduced the patient perceived burden of the investigation [29]. We gained insufficient 
self-reported data from participants to accurately assess reasons for non-compliance. 
Bruwer et al noted the unpleasant experience of bowel preparation to have a 
significantly negative impact on adherence to surveillance (16.4%) in this population 
group [1]. Despite this report, we found only 3 of the 72 (4.17%) colonoscopy 
outcomes failed due to poor colonic preparation. There was a remarkably positive 
adherence to bowel preparation in those individuals attending surveillance. In this 
study only two patients reported not attending surveillance due to poor tolerance of 
bowel preparation. 
We acknowledge there are limitations to our study. Despite the research group’s 
methods to limit interaction between family members we cannot confirm nor exclude 
that there was communication between individuals living in various towns across the 
Northern Cape Province. Almost one third of the study group, 27 individuals not 
presenting for surveillance in both study years, did not participate in subjective 
evaluations of justifications for non-compliance. Thus, the research team cannot 
accurately comment on the reasons for non-attendance in this study. 
 
Conclusion 
Direct interaction with Lynch syndrome individuals prior to annual surveillance 
colonoscopy has not shown to positively influence attendance. In the setting of limited 
resources within a large area of distribution, efforts to improve CRC surveillance need 
to be better focused. Yearly indirect contact with individuals known to be compliant 
appears to be an adequate method of retaining adherence. The Annual Northern Cape 
Colonoscopy Outreach program’s preparation trip should focus on interaction and 
counselling directed at individuals identified to be defaulting surveillance. 
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Tables and figures 
 
Table 6: Participant grouping as per Northern Cape towns 
Group 
number 
Town groupings Number of 
subjects 
Intervention year 
1 Upington  7 2015 
2 Kakamas 5 2015 
3 Buffelsrivier +Aggenys  9 2014 
4 Keimoes + Britstown + 
Brandvlei + Vanrhynsdorp 
6 2015 
5 Garies + Hondeklip Bay + 
Lelifontein 
8 2015 
6 Steinkopf  5 2015 
7 Okiep + Eksteenfontein + 
Springbok 
7 2014 
8 Kommagas 9 2014 
9 Port Nolloth + Nababeep  7 2015 
10 Kharkhams + Nourivier 6 2014 
11 Clanwilliam + Vredendal 4 2014 
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Table 7: Participant demographics by intervention group 
 






Male 34.21%(13) 37.5%(15) 35.9%(28) 
Female 65.79%(25) 62.5%(25) 64.1%(50) 
Mean age (range) 42.37(25-78) 41.23(25-74) 41.78 
Median age (range) 38.5(25-78) 40.5(25-74) 39.5 
Travel distance     
     Mean (km) 108.34 141,68 125.44 
     0-50km (n) 26.32%(10) 22.5%(9) 24.36%(19) 
     50-100km (n) 42.11%(16) 15%(6) 28.2%(22) 
     100-200km (n) 18.42%(7) 42.5%(17) 30.77%(24) 
     200-300km (n) 7.89%(3) 12.5%(5) 10.26%(8) 
     >300km (n) 5.26%(2) 7.5%(3) 6.41%(5) 
Transport    
     Own (n) 39.47%(15) 35%(14) 37.18%(29) 
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Table 8: Effects of variables on primary outcome (95% CI) 
 
Coefficient 
Std. Err.* p-value 
Gender .058957 .4227125 0.889 
Age .0048007 .0151083 0.751 
Previous scopes 
attended 
.1981803 .0586155 0.001 
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Fig. 3: Preparation trip towns in the Northern Cape Province of South Africa 
 
 
Fig. 4: Schematic of Harefield Cleansing Scale [21] 
 
	   53	  
































Parameters: ! = .05, 1-" = .9, # = -.2, p1+ = .7, p+1 = .5
Large-sample McNemar's test
H0: p+1 = p1+  versus  Ha: p+1 $ p1+
Estimated sample size for a two-sample paired-proportions test
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Fig. 6: CONSORT diagram 
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Fig. 8: Individual attendance to surveillance based on prior attendance 
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Chapter 3 – Appendices 
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Appendix C – Consent form 
 
Consent	  Form	  to	  participate	  in	  medical	  
research	  
Surveillance colonoscopy for Lynch Syndrome in the Northern Cape: 
Does direct contact improve compliance? 
 
Dr. AC Coccia 
Supervisor 
Prof. PA Goldberg 
Department of Colorectal Surgery 
Groote Schuur Hospital 
 
Contact	  for	  research:	  	  Dr.	  AC	  Coccia	  (Tel:	  	  074	  124	  5542;	  e-­‐mail:	  	  
ac_coccia@yahoo.com)	  
	  
I,	  ___________________________	  hereby	  agree	  to	  participate	  in	  the	  research	  project	  
evaluating	  the	  requirement	  of	  a	  pre-­‐colonoscopy	  preparation	  trip.	  	  The	  risks	  and	  
benefits	  have	  been	  explained	  to	  me	  by	  Dr.	  AC	  Coccia	  and	  Sr.	  Ursula	  Algar	  which	  I	  
understand	  and	  have	  been	  given	  the	  opportunity	  to	  ask	  questions.	  	  	  
I	  understand	  that	  my	  participation	  in	  this	  study	  is	  entirely	  voluntary.	  	  
I	  understand	  there	  will	  not	  be	  any	  financial	  compensation	  involved	  for	  
participation	  in	  this	  research.	  	  	  
I	  agree	  to	  the	  use	  of	  my	  medical	  records	  which	  might	  include	  a	  physical	  
examination	  and	  personal	  information.	  	  This	  will	  remain	  confidential	  but	  may	  be	  
used	  for	  presentations	  and	  articles	  (on	  an	  anonymous	  basis).	  
	  
	  
________________________	   	   	   	   	   	   _____________________	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Appendix D – Questionnaire 
 
Questionnaire 
Patient experience of preparation for colonoscopy 
 
 
Surveillance colonoscopy for Lynch Syndrome in the Northern Cape: 
Does direct contact improve compliance? 
 
 




Prof. PA Goldberg 
Department of Colorectal Surgery 
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Please tick the appropriate block 
 
1. Have you ever had a colonoscopy before? 
□Yes   □No	  
	  
2. If yes, how many previous screening colonoscopies have you had? 
    
 
3. Have you attended all your screening colonoscopy appointments? 
□Yes   □No	  
	  
4. If not, what was the reason for not attending? 
                                                                         . 
	  
5. Prior to the colonoscopy, did you receive a pamphlet or booklet explaining what  
    the test involved? 
□Yes   □No	  
	  
6. If you did received a pamphlet or booklet:  
a. Did it explain the preparation in a clear manner? 
□Yes    □No	  
b. Did it explain the procedure in a clear manner? 
□Yes    □No	  
	  
7. Did you understand the information given in the pamphlet/booklet? 
□Yes   □No	  
	  
8. Prior to the date of your colonoscopy, did you meet with a nurse or doctor from    
    Cape Town? 
□Yes   □No	  
	  
9. Did the nurse or doctor discuss with you what the test involved? 
□Yes   □No	  
	  
10. If so, was there any additional information given by the nurse or doctor that was   
      not covered in the pamphlet/booklet? 
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11. Do you feel it would help to have a meeting with a nurse or doctor prior to your                     
      colonoscopy? 
□Yes   □No	  
	  
12. Would you prefer to have a meeting with a nurse or doctor prior to the date of  
      your colonoscopy? 
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Appendix E – Instructions to authors 
 
International Journal of Colorectal Disease 
 
Text Formatting 
Manuscripts should be submitted in Word. 
Use a normal, plain font (e.g., 10-point Times Roman) for text.   
Use italics for emphasis. 
Use the automatic page numbering function to number the pages. 
Do not use field functions. 
Use tab stops or other commands for indents, not the space bar. 
Use the table function, not spreadsheets, to make tables. 
Use the equation editor or MathType for equations. 
Save your file in docx format (Word 2007 or higher) or doc format (older Word 
versions). 
Manuscripts with mathematical content can also be submitted in LaTeX. 
LaTeX macro package (zip, 182 kB) 
 
Headings 
Please use no more than three levels of displayed headings. 
 
Abbreviations 
Abbreviations should be defined at first mention and used consistently thereafter. 
 
Footnotes 
Footnotes can be used to give additional information, which may include the citation 
of a reference included in the reference list. They should not consist solely of a 
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reference citation, and they should never include the bibliographic details of a 
reference. They should also not contain any figures or tables. 
 
Footnotes to the text are numbered consecutively; those to tables should be indicated 
by superscript lower-case letters (or asterisks for significance values and other 
statistical data). Footnotes to the title or the authors of the article are not given 
reference symbols. Always use footnotes instead of endnotes. 
 
Citation 
Reference citations in the text should be identified by numbers in square brackets. 
Some examples: 
1. Negotiation research spans many disciplines [3]. 
2. This result was later contradicted by Becker and Seligman [5]. 
3. This effect has been widely studied [1-3, 7]. 
 
Reference list 
The list of references should only include works that are cited in the text and that have 
been published or accepted for publication. Personal communications and unpublished 
works should only be mentioned in the text. Do not use footnotes or endnotes as a 
substitute for a reference list. 
The entries in the list should be numbered consecutively. 
Always use the standard abbreviation of a journal’s name according to the ISSN List 
of Title Word Abbreviations. 
 
Tables  
All tables are to be numbered using Arabic numerals. Tables should always be cited in 
text in consecutive numerical order. For each table, please supply a table caption (title) 
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explaining the components of the table. Identify any previously published material by 
giving the original source in the form of a reference at the end of the table caption. 
Footnotes to tables should be indicated by superscript lower-case letters (or asterisks 
for significance values and other statistical data) and included beneath the table body. 
 
Figures 
To add lettering, it is best to use Helvetica or Arial (sans serif fonts).  
Keep lettering consistently sized throughout your final-sized artwork, usually about 2–
3 mm (8–12 pt).  
Variance of type size within an illustration should be minimal, e.g., do not use 8-pt 
type on an axis and 20-pt type for the axis label. 
Avoid effects such as shading, outline letters, etc. 
Do not include titles or captions within your illustrations. 
All figures are to be numbered using Arabic numerals. 
Figures should always be cited in text in consecutive numerical order. 
Figure parts should be denoted by lowercase letters (a, b, c, etc.). 
If an appendix appears in your article and it contains one or more figures, continue the 
consecutive numbering of the main text. Do not number the appendix figures, "A1, 
A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) 
should, however, be numbered separately. 
Each figure should have a concise caption describing accurately what the figure 
depicts. Include the captions in the text file of the manuscript, not in the figure file. 
Figure captions begin with the term Fig. in bold type, followed by the figure number, 
also in bold type. 
No punctuation is to be included after the number, nor is any punctuation to be placed 
at the end of the caption. 
Identify all elements found in the figure in the figure caption; and use boxes, circles, 
etc., as coordinate points in graphs. 
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Identify previously published material by giving the original source in the form of a 
reference citation at the end of the figure caption. 
Figures should be submitted separately from the text, if possible. 
When preparing your figures, size figures to fit in the column width. 
 
Informed consent 
The following statement should be included: 
Informed consent: “Informed consent was obtained from all individual participants 
included in the study.” 
If identifying information about participants is available in the article, the following 
statement should be included: 
“Additional informed consent was obtained from all individual participants for whom 
identifying information is included in this article.” 
 
